ArticlePediatric transplantation2025
Novel Use of Bland Trans-Arterial Embolization for Hepatoblastoma: A Case Report.
Article in Pediatric transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Novel Use of Bland Trans-Arterial Embolization for Hepatoblastoma: A Case Report.Pediatric transplantation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatoblastoma is an embryonal tumor originating from hepatocyte precursors. Surgical resection is the primary treatment. Unresectable cases are treated with chemotherapy combined with liver transplantation. Patients with suboptimal chemotherapy response face limited therapeutic choices. Trans-arterial radioembolization (TARE), trans-arterial chemoembolization (TACE), and bland trans-arterial embolization (TAE) are therapeutic radiologic techniques that preferentially utilize blood supply for liver tumors to deliver microspheres to the tumor. These radiologic techniques used in pediatrics are limited to relapsed diseases or for palliation.
methodsWe describe the case of the youngest patient with hepatoblastoma to undergo TARE-Y90 and the first pediatric patient to undergo TAE as a bridge to liver transplantation.
resultsA 12-month-old boy, born prematurely at 25 weeks' gestation, was found to have PRETEXT III, intermediate-risk, non-metastatic, unresectable hepatoblastoma. His initial alpha-fetoprotein (AFP) was elevated to 2,140,000 ng/mL. Systemic chemotherapy had minimal response, and escalation of chemotherapy was unsuccessful, raising concern for chemotherapy resistance. After multidisciplinary discussion, he underwent TARE-Y90 with tumor response by imaging and improved AFP. However, his disease remained unresectable. TAE was performed twice as a bridge to liver transplant, followed by another chemotherapy cycle to minimize metastasis. Both procedures had minimal complications.
conclusionsThis case represents the successful use of TARE and TAE for chemotherapy-resistant hepatoblastoma to reduce tumor burden and to allow for curative liver transplant in a pediatric patient. Short-term outcomes are promising as he underwent cadaveric liver transplantation and continues to do well without evidence of recurrence, 2 years off therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.